Business
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, is pleased to announce the appointment of Dr. Olga Nissan as its Vice President of Business Development, effective as of January 1, 2026.
About this update from Teva Pharmaceutical Industries Limited
[{"type":"text","content":"REHOVOT, Israel, Dec. 30, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, is pleased to announce the appointment of Dr. Olga Nissan as its Vice President of Business Development, effective as of January 1, 2026.","length":388,"tagName":"p"},{"type":"image","alt":"Dr. Olga Nissan, Vice President of Business Development, Evogene Ltd.","displaySize":"","headline":null,"caption":"Dr. Olga Nissan, Vice President of Business Development, Evogene Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":324,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/6c6ccb6f722249363dc9a6530741b393"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hSZ7qNUUAPOdcwWAaoJlUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTc5MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/6c6ccb6f722249363dc9a6530741b393","width":324,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/hSZ7qNUUAPOdcwWAaoJlUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTc5MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/6c6ccb6f722249363dc9a6530741b393","width":324,"height":400}},"href":"https://mma.prnewswire.com/media/2852394/Olga_Nissan.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Nissan is a seasoned biotechnology and pharmaceutical executive with extensive experience in bridging science, business, and funding. She has a proven track record of leading R&D, clinical development, and business operations across the pharmaceutical, diagnostics, and agri-biotechnology sectors. Her prior roles include CEO and Co-Founder of Protica Bio, Technology Manager at EcoPhage, Senior Scientist at BiomX, and QC Domain Manager at Teva Pharmaceutical Industries.","length":480,"tagName":"p"},{"type":"text","content":"Dr. Nissan holds a PhD and completed postdoctoral research in the fields of biochemistry and proteomics, from the Weizmann Institute of Science.","length":144,"tagName":"p"},{"type":"text","content":""I am excited to join Evogene at a pivotal time in its expansion," said Dr. Olga Nissan. "The company's commitment to translating cutting-edge, AI-driven science into meaningful small-molecule-based therapeutic value, strongly...